Bicycle Therapeutics PLC (BCYC) stock
BCYCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 11/3081% below fair value
$3.05−0.06 (-1.93%)
Close on Nov 19, 2026Market cap $213.79MP/E –Yield 0.00%
Bicycle Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Bicycle Therapeutics's free cash flow for the twelve months ending Sep 30, 2026 was -$177.04M. For fiscal 2025 it was -$252.03M. The highest annual figure on record is -$2.53M in fiscal 2017.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$252.03M | – |
| FY2024 | Dec 31, 2024 | -$165.96M | – |
| FY2023 | Dec 31, 2023 | -$63.56M | – |
| FY2022 | Dec 31, 2022 | -$105.10M | – |
| FY2021 | Dec 31, 2021 | -$16.82M | – |
| FY2020 | Dec 31, 2020 | -$18.99M | – |
| FY2019 | Dec 31, 2019 | -$30.17M | – |
| FY2018 | Dec 31, 2018 | -$27.26M | – |
| FY2017 | Dec 31, 2017 | -$2.53M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$40.61M | – |
| Q2 FY2026 | Jun 30, 2026 | -$49.87M | – |
| Q1 FY2026 | Mar 31, 2026 | -$66.64M | – |
| Q4 FY2025 | Dec 31, 2025 | -$19.92M | – |
| Q3 FY2025 | Sep 30, 2025 | -$71.85M | – |
| Q2 FY2025 | Jun 30, 2025 | -$73.28M | – |
| Q1 FY2025 | Mar 31, 2025 | -$86.97M | – |
| Q4 FY2024 | Dec 31, 2024 | -$9.76M | – |
| Q3 FY2024 | Sep 30, 2024 | -$40.27M | – |
| Q2 FY2024 | Jun 30, 2024 | -$45.05M | -233.2% |
| Q1 FY2024 | Mar 31, 2024 | -$70.88M | – |
| Q4 FY2023 | Dec 31, 2023 | -$47.34M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.53M | – |
| Q2 FY2023 | Jun 30, 2023 | $33.82M | – |
| Q1 FY2023 | Mar 31, 2023 | -$48.51M | – |
| Q4 FY2022 | Dec 31, 2022 | -$31.76M | – |
| Q3 FY2022 | Sep 30, 2022 | -$8.86M | -141.1% |
| Q2 FY2022 | Jun 30, 2022 | -$33.33M | – |
| Q1 FY2022 | Mar 31, 2022 | -$31.16M | – |
| Q4 FY2021 | Dec 31, 2021 | -$11.50M | – |
| Q3 FY2021 | Sep 30, 2021 | $21.55M | – |
| Q2 FY2021 | Jun 30, 2021 | -$12.54M | – |
| Q1 FY2021 | Mar 31, 2021 | -$14.33M | -168.8% |
| Q4 FY2020 | Dec 31, 2020 | -$17.10M | – |
| Q3 FY2020 | Sep 30, 2020 | -$10.08M | – |
| Q2 FY2020 | Jun 30, 2020 | -$12.65M | – |
| Q1 FY2020 | Mar 31, 2020 | $20.84M | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.31M | – |
| Q3 FY2019 | Sep 30, 2019 | -$11.17M | – |
| Q2 FY2019 | Jun 30, 2019 | -$8.07M | – |
| Q1 FY2019 | Mar 31, 2019 | -$5.62M | – |
| Q4 FY2018 | Dec 31, 2018 | -$9.26M | – |
| Q3 FY2018 | Sep 30, 2018 | -$4.78M | – |
See a number that looks wrong?